Indication
Bacterial endocarditis
Bacterial endocarditis is an invasive infection and inflammation of the endocardium, most frequently involving native or prosthetic heart valves, mural endocardium, or implanted intracardiac devices. Read more about Bacterial endocarditis
119 drugs 60 manufacturers
Drugs that treat it
Common Bacterial endocarditis therapies.
IMIPENEM-CILASTATIN SODIUM (imipenem/cilastatin sodium)
VANCOMYCIN HCL
IMIPENEM-CILASTATIN SODIUM (imipenem/cilastatin sodium)
CEFAZOLIN SODIUM
AMPICILLIN SODIUM
VANCOMYCIN HCL
VANCOMYCIN HCL
VANCOMYCIN HCL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonBacterial endocarditis is an invasive infection and inflammation of the endocardium, most frequently involving native or prosthetic heart valves, mural endocardium, or implanted intracardiac devices.
It primarily affects the cardiovascular system, with heightened vulnerability among individuals with preexisting valvular disease, congenital cardiac anomalies, prosthetic materials, or history of intravenous drug use.
Pathophysiologically, circulating bacteria—predominantly staphylococci, streptococci, or enterococci—colonize damaged endocardial surfaces or thrombi, forming infected vegetations composed of fibrin, platelets, and microorganisms.
This process leads to progressive tissue destruction, acute or subacute valvular dysfunction, sustained bacteremia, and a high risk of life-threatening systemic embolization.
- nih.gov
Bacterial endocarditis is an invasive infection and inflammation of the endocardium, most frequently involving native or prosthetic heart valves, mural endocardium, or implanted intracardiac devices This process leads to progressive tissue destruction, acute or subacute valvular dysfunction, sustained bacteremia, and a high risk of life-threatening systemic embolization
- nih.gov
It primarily affects the cardiovascular system, with heightened vulnerability among individuals with preexisting valvular disease, congenital cardiac anomalies, prosthetic materials, or history of intravenous drug use
- medlineplus.gov
It primarily affects the cardiovascular system, with heightened vulnerability among individuals with preexisting valvular disease, congenital cardiac anomalies, prosthetic materials, or history of intravenous drug use
- nih.gov
Pathophysiologically, circulating bacteria—predominantly staphylococci, streptococci, or enterococci—colonize damaged endocardial surfaces or thrombi, forming infected vegetations composed of fibrin, platelets, and microorganisms
- nih.gov
Pathophysiologically, circulating bacteria—predominantly staphylococci, streptococci, or enterococci—colonize damaged endocardial surfaces or thrombi, forming infected vegetations composed of fibrin, platelets, and microorganisms
- nih.gov
This process leads to progressive tissue destruction, acute or subacute valvular dysfunction, sustained bacteremia, and a high risk of life-threatening systemic embolization
Personalize your experience
Follow Bacterial endocarditis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.